









市場行情
/
股票
/
nasdaq-avdl
/

Avadel Pharmaceuticals PLC

AVDL

21.590USD

+0.010+0.05%

收盤 12/26, 16:00（美東）報價延遲15分鐘

2.10B總市值

虧損本益比TTM



Avadel Pharmaceuticals PLC

21.590

+0.010+0.05%

概覽公司財務分析

概覽

公司

財務

分析

關於 Avadel Pharmaceuticals PLC 公司

Avadel Pharmaceuticals PLC is a biopharmaceutical company. The Company's product, LUMRYZ, is an extended-release formulation of sodium oxybate, indicated to be taken once at bedtime for the treatment of cataplexy or excessive daytime sleepiness (EDS) in adults with narcolepsy. Its approach includes applying solutions to the development of medications that address the challenges patients face with treatment options. Its drug delivery technologies include MICROPUMP, LIQUITIME, and MEDUSA. Its MICROPUMP technology allows for the development of modified-release solid, oral dosage formulations of drugs. Its LIQUITIME technology allows for the development of modified-release oral products in a liquid suspension formulation, which may make such formulations particularly suited for children and/or patients having issues swallowing tablets or capsules. Its MEDUSA technology allows for the development of modified-release injectable dosage formulations of drugs.

Avadel Pharmaceuticals PLC簡介



公司代碼AVDL

公司名稱Avadel Pharmaceuticals PLC

上市日期Feb 21, 2088

CEODivis (Gregory J)

員工數量188

證券類型Ordinary Share

年結日Feb 21

公司地址Block 10-1 Blanchardstown Corporate Park

城市DUBLIN

上市交易所NASDAQ OMX - NASDAQ BASIC

國家Ireland

郵編15

電話35319015201

網址https://www.avadel.com/

公司代碼AVDL

上市日期Feb 21, 2088

CEODivis (Gregory J)

Avadel Pharmaceuticals PLC公司高管



名稱

名稱/職務

職務

持股

持股變動

Dr. Eric J. Ende, M.D.

Independent Director

219.90K

Mr. Peter J. Thornton

Independent Director

115.06K

Mr. Thomas S. Mchugh

Chief Financial Officer

100.40K

+14.35%

Dr. Mark Anthony Mccamish, M.D., Ph.D.

Independent Director

89.03K

Ms. Linda S. Palczuk

Independent Director

78.90K

Ms. Susan Rodriguez

Chief Operating Officer

Mr. Jerad Seurer

General Counsel and Corporate Secretary

Mr. Gregory J. (Greg) Divis, Jr.

Chief Executive Officer, Director

Dr. Naseem Amin, M.D.

Independent Director

Ms. Courtney Turiano

Investor Relations

名稱

名稱/職務

職務

持股

持股變動

Dr. Eric J. Ende, M.D.

Independent Director

219.90K

Mr. Peter J. Thornton

Independent Director

115.06K

Mr. Thomas S. Mchugh

Chief Financial Officer

100.40K

+14.35%

Dr. Mark Anthony Mccamish, M.D., Ph.D.

Independent Director

89.03K

Ms. Linda S. Palczuk

Independent Director

78.90K

Ms. Susan Rodriguez

Chief Operating Officer

收入明細

單位: USD更新時間: 3月3日週一

FY2020

FY2019

業務USD

名稱

營收

佔比

Vazculep

10.43M

46.70%

Akovaz

9.54M

42.74%

Bloxiverz

2.20M

9.85%

Other

159.00K

0.71%

地區USD

名稱

營收

佔比

United States

22.33M

100.00%

Ireland

0.00

0.00%

業務

地區

業務USD

名稱

營收

佔比

Vazculep

10.43M

46.70%

Akovaz

9.54M

42.74%

Bloxiverz

2.20M

9.85%

Other

159.00K

0.71%

股東統計

更新時間: 12月7日週日

持股股東

股東類型

持股股東

佔比

Janus Henderson Investors

7.57%

BlackRock Institutional Trust Company, N.A.

6.26%

The Vanguard Group, Inc.

5.98%

Brandes Investment Partners, L.P.

5.55%

Two Seas Capital LP

5.47%

其他

69.17%

持股股東

佔比

Janus Henderson Investors

7.57%

BlackRock Institutional Trust Company, N.A.

6.26%

The Vanguard Group, Inc.

5.98%

Brandes Investment Partners, L.P.

5.55%

Two Seas Capital LP

5.47%

其他

69.17%

股東類型

持股股東

佔比

Investment Advisor

33.38%

Investment Advisor/Hedge Fund

31.72%

Hedge Fund

21.03%

Research Firm

4.62%

Venture Capital

3.46%

Individual Investor

1.06%

Pension Fund

0.46%

Bank and Trust

0.36%

Insurance Company

0.03%

其他

3.89%

機構持股



更新時間: 12月8日週一

報告期間

機構數

持股數

持股佔比

持股變動

2025Q4

402

92.83M

119.15%

+3.65M

2025Q3

398

82.11M

112.88%

-1.35M

2025Q2

383

83.11M

109.34%

+2.70M

2025Q1

369

80.46M

107.15%

-23.08M

2024Q4

346

82.09M

100.78%

+4.35M

2024Q3

324

77.51M

94.69%

+670.00K

2024Q2

289

76.58M

80.85%

+4.27M

2024Q1

248

72.03M

68.66%

+6.05M

2023Q4

216

57.48M

70.10%

+1.83M

2023Q3

210

56.27M

69.82%

+253.21K

股東持股明細



名稱

持股數

佔比

持股變動

變動比例

公告日期

Janus Henderson Investors

11.13M

11.46%

-2.46M

-18.10%

Jun 30, 2025

BlackRock Institutional Trust Company, N.A.

5.98M

6.16%

+1.29M

+27.56%

Jun 30, 2025

The Vanguard Group, Inc.

5.54M

5.71%

+1.66M

+42.73%

Jun 30, 2025

Brandes Investment Partners, L.P.

6.49M

6.68%

+820.47K

+14.48%

Jun 30, 2025

Two Seas Capital LP

6.16M

6.34%

+1.21M

+24.43%

Jun 30, 2025

Tontine Asset Management, LLC

5.18M

5.33%

-950.54K

-15.51%

Jun 30, 2025

Polar Capital LLP

4.00M

4.12%

-356.63K

-8.19%

Jun 30, 2025

Vivo Capital, LLC

2.68M

2.76%

Jun 30, 2025

State Street Investment Management (US)

2.07M

2.13%

+412.10K

+24.84%

Jun 30, 2025

持股ETF



更新時間: 12月6日週六

機構名稱

佔比

Innovator IBD 50 Fund ETF

3.77%

Invesco Pharmaceuticals ETF

3.4%

iShares Neuroscience and Healthcare ETF

3.21%

ProShares Merger ETF

2.82%

State Street SPDR S&P Pharmaceuticals ETF

2.44%

Direxion Daily Pharmaceutical & Medical Bl 3X ETF

2.39%

AltShares Event-Driven ETF

1.21%

First Trust Small Cap Growth AlphaDEX Fund

1.02%

iShares U.S. Pharmaceuticals ETF

0.68%

Janus Henderson Small/Mid Cap Growth Alpha ETF

0.4%

Innovator IBD 50 Fund ETF

佔比3.77%

Invesco Pharmaceuticals ETF

佔比3.4%

iShares Neuroscience and Healthcare ETF

佔比3.21%

ProShares Merger ETF

佔比2.82%

State Street SPDR S&P Pharmaceuticals ETF

佔比2.44%

Direxion Daily Pharmaceutical & Medical Bl 3X ETF

佔比2.39%

AltShares Event-Driven ETF

佔比1.21%

First Trust Small Cap Growth AlphaDEX Fund

佔比1.02%

iShares U.S. Pharmaceuticals ETF

佔比0.68%

Janus Henderson Small/Mid Cap Growth Alpha ETF

佔比0.4%

分紅派息



近5年累計派現 0.00 美元

公告日期

分紅計劃

股權登記日

現金發放日

除權除息日

暫無數據

拆合股



公告日期

類型

比率

暫無數據

公告日期

類型

比率

暫無數據

常見問題

Avadel Pharmaceuticals PLC的前五大股東是誰？



Avadel Pharmaceuticals PLC的前五大股東如下：
Janus Henderson Investors
持有股份：11.13M
佔總股份比例：11.46%。
BlackRock Institutional Trust Company, N.A.
持有股份：5.98M
佔總股份比例：6.16%。
The Vanguard Group, Inc.
持有股份：5.54M
佔總股份比例：5.71%。
Brandes Investment Partners, L.P.
持有股份：6.49M
佔總股份比例：6.68%。
Two Seas Capital LP
持有股份：6.16M
佔總股份比例：6.34%。